Relacionalidad y ética en la terapia asistida con MDMA (Beachy, et al, 2025)
Para brindar una atención segura y eficaz a los pacientes de MAT será necesario integrar nuestra atención en un marco de ética relacional, manteniendo límites terapéuticos positivos y fomentando un entorno terapéutico sensible y receptivo. Un entorno profesional de apoyo donde se cultiven activamente la curiosidad, la autorreflexión y las conversaciones abiertas será el mejor apoyo para estos esfuerzos.
MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for ptsd (clinicaltrials.gov)
Sponsor Dr. Leslie Morland San Diego #veterans Healthcare System — #mdma research is robust and ongoing, with studies addressing the weak/sloppy areas outlined in the #fda Lykos/MAPS new drug application. #psychedelics #mdma #psychedelic #psychedelicresearch
June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)
Briefing document— https://www.fda.gov/media/178984/download and public comments— https://www.regulations.gov/document/FDA-2024-N-1938-0001/comment #mdma #psychedelic #fda #mdmaassistedtherapy #psychedelics #ptsd #mentalhealth #psychedelicresearch
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults (Danforth, et al, 2016)
Pure MDMA used in approved clinical settings is far safer than recreational use of Ecstasy or Molly.
•
MDMA-assisted therapy could reduce social anxiety symptoms and increase social adaptability.
•
The need to develop effective treatments for social anxiety in autistic adults is presently unmet.
•
MDMA does not require ongoing administration to achieve lasting benefits
Updated Research on MDMA
Big Money Is Taking Over MDMA-Assisted Therapy
Nonprofit MAPS promised to bring therapeutic MDMA to market on the back of philanthropic donations. But then it morphed into a for-profit concern — and with FDA approval looming, Big Pharma is trying to get in on the act.
As investors pile into psychedelics, idealism gives way to pharma economics
For more than 30 years, MAPS' efforts have been funded almost entirely by donations from wealthy individuals, including billionaires like New York Mets owner Steven Cohen and Republican political donor Rebekah Mercer. On principle, MAPS has never patented its work.
The group’s pharmaceutical arm, the MAPS Public Benefit Corp., is expected to win U.S. approval this year for the first psychedelic medicine accepted for review by the Food and Drug Administration: MDMA, or ecstasy, to help treat post-traumatic stress disorder.